Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have gained 638% in 2026. The past week showed how quickly a move like that can give ground: the stock dropped 14.33%. Jim Cramer interviewed Moderna CEO Stéphane Bancel at the company’s Analyst Day during the November 12 edition of Mad Money. Investors now have to consider how much of the cancer vaccine story a $90.38 billion valuation already includes.
One Melanoma Headline Rewrote Moderna’s Year
Jim Cramer reminded viewers that Moderna was a $63 stock on August 18. Cramer said it closed above $174 the next day, after Moderna and Merck (NYSE:MRK) reported that adding their personalized cancer shot to Merck’s Keytruda helped keep melanoma from coming back after surgery. Jim Cramer said the stock was up more than 680% for 2026 as of that show, and current data puts the gain lower, at 638%.
Cramer had already described the shift on October 1: Moderna, “formally viewed as a one trick Covid pony now is something that could be huge in cancer. I think it verifies the excitement and the move.”
Bancel’s Timeline Points to a 2027 Launch
Bancel described how the product is made: “We make a product for one human at a time, where we put in a cassette of one mRNA molecule with 34 mutations of the cancer of that patient. It’s injected intramuscularly every three weeks for nine doses.” He also told Cramer the “data are fantastic.”
On timing, Bancel said Moderna and Merck are “working very, very deliberately to try to get the filing to the FDA before the end of the year,” and that with a good regulatory review the shot could reach Americans in 2027. He added that the New England Journal of Medicine had published the full data the night before the interview.
What the Melanoma Result Means for Patients
The Phase 3 trial enrolled more than 1,100 patients[1] whose melanoma had been surgically removed. Adding intismeran to Keytruda lowered the risk of recurrence or death by 42%[2] compared with Keytruda alone (hazard ratio 0.58). Put simply, 70%[1] of patients on Keytruda alone were recurrence-free after two years, compared with 82.2% on the combination. Merck co-develops the therapy with Moderna and shares costs and profits, so Moderna gets a commercial partner that already sells Keytruda to oncologists.
Upcoming Catalysts for Moderna
- Kidney cancer: A 282-patient[1] Phase 2 study could read out “the end of this year or early next year.”
- Multiple myeloma: mRNA-2808 gets an oral presentation at ASH on December 12.
- Rare disease: Pivotal propionic acidemia data is expected in 2026[2].
Vaccine Sales Are Paying for the Cancer Push
According to Moderna’s third-quarter earnings release, revenue rose 29.2%[2] to $1.31 billion, ahead of the $891.31 million consensus. EPS came in at $0.38[2], while analysts had expected a loss of $1.28. Management raised its 2026 revenue growth outlook to 15%-25%[2] from up to 10% and now expects year-end cash of $8.1-$8.3 billion. More details are on Moderna’s investor relations site.
Risks That Could Hit a 638% Winner
- Revenue still depends heavily on COVID vaccines and government contracts.
- Debt rose after about a $3.0 billion[2] convertible note offering.
- The norovirus vaccine did not meet early success criteria[2] at its Phase 3 interim analysis.
- Management has offered no specific pricing guidance[1] for intismeran, and approval still requires FDA sign-off.
Does Cramer’s Enthusiasm Hold Up at Today’s Price?
The clinical evidence backs up Cramer’s view. The melanoma data held up in a large trial; the full results are published, and a filing is planned within weeks. The valuation already reflects much of that. Shares hit $254.19 the day after earnings and have since fallen to $223.37. A positive kidney cancer readout would show the platform works beyond one tumor type, and that is what the next gain likely depends on. Expect more volatility, and track the stock around the FDA filing and the kidney cancer data.
Contact [email protected] for any questions or corrections.





